Videos

Explore rapid TRD breakthroughs: accelerated TMS like SAINT, emerging neuromodulation tools, near-term psychedelic therapies, and why sharper diagnosis improves outcomes.

Consensus guidance clarifies IV ketamine dosing, monitoring, staffing and consent to support safer, evidence-based depression treatment.

Experts urge metabolic screening across psychiatric diagnoses, spotlighting tailored interventions and tools like PsyMetRiC—while warning risk talks can backfire.

New Delphi consensus guides off-label IV ketamine for depression, detailing protocols and rapid antisuicidal mechanisms via neuroplasticity and BDNF.

PP-01 targets CB-1 recovery and dopamine balance, aiming to ease cannabis withdrawal and boost abstinence as a fast-tracked phase 3 trial advances.

In the final episode, "Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy," David Walling, PhD, explored how these findings add to the evolving evidence base for Cobenfy in schizophrenia, and what questions remain for future research.

New data in cannabis use disorder show investigational drug PP-01 cuts irritability 42% in trials.

Therapeutic drug monitoring clarifies adherence and plasma levels, while long-acting injectables and patches reduce variability and support patient-centered benefit-risk decisions.

Clinicians weigh oral, LAI and transdermal antipsychotics, urging early use, adherence focus, and side-effect education to optimize outcomes.

Expert explains why Alzheimer disease remains complex, how biomarkers and imaging track amyloid, and what new anti-tau and anti-inflammatory drugs emerge.

Physician burnout persists as moral injury grows in psychiatry, with July 4 reflection on systemic healthcare failures, ethical compromise, and peer-supported recovery.

Explore how major holidays like July 4 can trigger PTSD, loneliness, and grief—and why psychiatrists can help patients prepare for emotional fallout.

Explore psychiatry’s roots, breakthroughs, and ethical issues—from Rush to DSM debates—and why AI and psychedelics could reshape care.

Expert explores fast-acting depression treatments, psilocybin trial pitfalls, and why stigma still limits buprenorphine access for opioid use disorder.

As America nears 250 years, a psychiatrist argues independence is core to mental health, urging clinicians to fight stigma and restore autonomy.

Explore how to manage mood and substance use disorders together, boost engagement, and expand addiction medications.

In "Managing Tolerability and Setting Patients Up for Success with Cobenfy," David Walling, PhD, delved into the key tolerability considerations for patients with schizophrenia transitioning to Cobenfy and how clinicians should proactively manage gastrointestinal side effects?

Why psychiatry’s growing “tribalism” harms care—and how clinicians, academia, and pharma can unite to tackle untreated mental illness.

This episode, titled "Integrating Novel Mechanisms into Schizophrenia Treatment Practice," features panelist Mark Jankelow discussing the practical clinical considerations surrounding a novel muscarinic agent.

Explore 2024’s xanomeline–trospium: M1/M4 muscarinic therapy for schizophrenia, easing EPS and metabolic risks while raising GI concerns.

Expert shares ADHD medication sequencing tips and practical insomnia strategies, from stimulants to melatonin, for kids and adults.

New phase 3 analyses show centanafadine improves adult ADHD executive function and emotional regulation beyond core symptoms, as FDA review advances toward July 2026.

New data suggest seltorexant may ease insomnia in MDD while limiting weight gain and potentially improving metabolic risk factors.

Phase 3 data show adjunctive seltorexant eases depression and insomnia with lessened weight gain and somnolence.

Explore how the asenapine transdermal patch helps schizophrenia care with steadier dosing, fewer side effects, and new options beyond sublingual pills.

Clinicians empower schizophrenia patients with shared decisions and flexible treatment options—oral, long-acting injectable, or transdermal—to improve adherence, trust, and remission potential.

Pediatric experts link insomnia and mental health, favor CBT over sedatives, and warn against cannabis for sleep.

Explore how circadian gene rhythms differ in schizophrenia, depression, and bipolar disorder—and why stable sleep timing may curb addiction risk.

Sleep and circadian rhythm disruption shape psychiatric symptoms and bipolar mood shifts.

MAPS probes psychedelic-assisted healing for formerly incarcerated people, spotlighting trauma, access barriers, and a public-health policy path.